Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8218928 | 0.94 | HDAC1 (0.56) | HDAC1HDAC6GPR119TRPV1NAMPT | |
| SCHEMBL8217835 | 0.91 | TRPV1 (0.55) | GPR119TRPV1USP30NR1H2RXRA | |
| SCHEMBL8217952 | 0.90 | HDAC1 (0.52) | HDAC1HDAC6GPR119TRPV1NAMPT | |
| SCHEMBL8214411 | 0.90 | GPR119 (0.56) | HDAC1HDAC6GPR119TRPV1NAMPT | |
| SCHEMBL8217831 | 0.88 | HDAC1 (0.53) | HDAC1HDAC6GPR119TRPV1NAMPT | |
| SCHEMBL8224617 | 0.85 | HDAC1 (0.53) | HDAC1HDAC6GPR119NAMPT | |
| SCHEMBL8212694 | 0.84 | TRPV1 (0.61) | HDAC1HDAC6GPR119TRPV1USP30 | |
| SCHEMBL8217839 | 0.84 | CACNA1H (0.49) | TRPV1USP30 | |
| SCHEMBL8225731 | 0.83 | CACNA1H (0.48) | GPR119TRPV1USP30 | |
| SCHEMBL8207926 | 0.83 | TRPV1 (0.51) | HDAC1HDAC6GPR119TRPV1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| WO-2008033460-A2 | TREATING PAIN, DIABETES, AND LIPID METABOLISM DISORDERS | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, CES1, ZDHHC20 | HDAC1 937/4885HDAC6 2818/4885GPR119 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.